exercises and cognitive strategies that can help individuals change unproductive thought patterns and behaviours to boost mental well being.
QOL as a measure of well-being has been studied in a variety of chronic medical conditions including allergic/atopic diseases. Reduced quality of life has been reported in patients/families with food allergies/asthma/ eczema. 1, 2, 3, 4 A systematic review and meta-analysis revealed a statistically significant bidirectional relationship between psychosocial factors and atopic disorders both for causation and prognosis 5 . This review supports the use of psychological interventions in addition to conventional physical and pharmacological therapies in atopic disorders.
Mindfulness based therapy has been shown to be effective in clinical populations with anxiety and mood disorders with or without chronic diseases.
6,7 A randomized controlled trial has shown lasting and clinically significant improvements in asthma-related QOL and stress in patients with persistent asthma after 8 weeks of mindfulness training 8 . A number of online resources are available to facilitate the 'practice of mindfulness' making it useful even in resource limited settings.
Incorporation of mindfulness in multi-model care of children and families with atopic conditions may contribute to improvement of their QOL. Preliminary evidence supports systematic exploration of 'mindfulness as a self-help tool' for mental well being. Her history includes a two-month of progressive left shoulder pain, followed by new right knee pain. This was associated with a reduced range of movement at both joints. There were no systemic symptoms. She continued to attend school, but had difficulties in doing sports and underwent physiotherapy with limited relief. An ultrasound of the shoulder was inconclusive. A subsequent MRI demonstrated bone marrow oedema at the proximal humeral head, scapula and lateral clavicle suggestive of CRMO. Her bloods at this time were within normal limits including haemoglobin, white cell count, neutrophil and a C-reactive protein. Her anti-nuclear antibody was also negative. There is no family history for any autoimmune diseases or allergies.
She was commenced on piroxicam 10mg once daily and prescribed MTX 15mg s.c weekly. She tolerated piroxicam well and received her first dose of MTX at the general practitioner (GP) clinic. Within nine minutes of her first dose, she reported a new onset headache, throat itch, difficulty breathing. An expiratory wheeze was present on clinical examination. No other possible trigger could be identified at this time and IM 0.5mg adrenaline was administered by the GP. An ambulance was called, with another dose of adrenaline given due to ongoing symptoms. In the Emergency Department, she had tachypnoea, with a biphasic stridor and wheeze. A third dose of IM adrenaline as well as inhaled salbutamol and oral dexamethasone were administered. Her symptoms resolved and she was admitted to the observations ward. Her blood counts as mast cell tryptase were all within range. She was discharged five hours later.
Discussion: Skin testing is in progress and further results and management will be discussed at the poster presentation. Background: The inception of focused hand hygiene programs has seen the widespread use of chlorhexidine hand-hygiene in health services. Since this time, there have been increasing reports of both immediate and delayed hypersensitivity to chlorhexidine among healthcare workers. There is little understanding of the potential occupational health impacts of chlorhexidine hand hygiene products.
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Objectives: Examine the prevalence of self-reported symptoms of sensitivity to chlorhexidine hand-hygiene among healthcare workers in a health service that primarily uses chlorhexidine-based hand hygiene products.
Methods: A cross-sectional online prevalence survey conducted in 2016-17.
Results: Of the 1050 responses, 76.3% were female, 35.3% were nurses and midwives and 28% medical staff; 8.7% did not work in clinical areas. Over 95% of all occupational groups reported using chlorhexidine-based hand-hygiene products in their workplace. Nurses and midwives most frequently reported a background history of asthma (13.7%) and contact dermatitis (27.8%); and previous testing for allergy to chlorhexidine (4.9%). In comparison, 11.9% of Medical staff reported a background history of asthma and 16.3% reported contact dermatitis. Dry skin was the most common symptom with chlorhexidine-based hand-hygiene products by Nursing (86.7%) and Medical (75%) staff. Allied health self-reported higher rates of eczema (45.2%) compared to nurses at (37.1%). Of note, 20.6% of nurses self-reported developing wheeze or cough on exposure to chlorhexidine based hand hygiene products. There was 1 report of anaphylaxis from a nurse.
Conclusions: Hospital hand hygiene programs decrease transmission of hospital acquired infections. Chlorhexidine based hand hygiene products have been adopted due to prolonged antimicrobial properties over alcohol only products. This study is reassuring in that the rate of self-reported anaphylaxis to chlorhexidine hand hygiene products was low, with the Method: A retrospective snap shot audit of 33 patients who were discharged from ED in 2017/18 was undertaken. Drug anaphylaxis N= 5 (16%) was excluded as an adrenaline auto injecting device is not usually indicated. The content of patient referrals, with and without an ADC and their electronic discharge summary were audited against the ADC criteria.
Results: Patients discharged from ED whose referral contained the ADC sticker scored significantly better compliance with discharge criteria relating to allergen avoidance advice N=6 (30%), adrenaline auto-injecting prescription N=12 (60%) inclusive of demonstration N=6 (30%) and anaphylaxis action plan N=14 (70%).
Case-note alert remains concerning low N=1 (5%).
The discharge management noted on the referral form and electronic discharge summary were inconsistent. When assessed for compliance with the ADC the electronic discharge summary content was deficient in documentation of discharge actions.
Conclusion:
The ADC sticker is a simple checklist for ED staff to effectively discharge patients at risk of anaphylaxis. Documentation of discharge care on referrals assists in triaging of referrals and risk management of patients whilst they are waiting for specialist appointments.
This audit provides evidence that a simple organized tool which aligns with current evidenced based anaphylaxis discharge criteria has a role within the clinical setting.
Combining an electronic patient ED referral/discharge summary which is inclusive of an ADC could further improve patient care at discharge. Background: Epidemiological studies conducted in America and Europe have reported a wide prevalence range of 0.5-7% for systemic reactions to insect stings in the general population. A recent Australian study using national hospital data from 2001 to 2013 identified that deaths due to anaphylaxis following insect envenomation occurred at a rate of 0.16 per 100 000 persons, with higher rates in males and in South Australia. However, there remains a lack of data regarding the epidemiology of insect allergy in Australia and thus we sought to identify the frequency of insect allergy within South Australia.
Methods: A prospective cross-sectional study was performed between September to December 2017, involving face-to-face surveys of South Australian community members. Subjects were selected via randomized stratified sampling. The survey included questions regarding reactions to insect stings, including local or systemic reactions and hospitalisation.
Results: A total of 2,977 subjects (57.0% response rate) responded to the survey, with the majority residing in a metropolitan area (81.7%). 754 (25.3%) of subjects reported a history of reactions to insect stings, with 677 respondents (22.7%) describing large local reactions. 116 (3.5%) subjects reported experiencing systemic symptoms such as difficulty breathing, vomiting and diarrhoea, or loss of consciousness. Nonmetropolitan respondents had a statistically significant increased rate of insect sting systemic reactions compared to metropolitan residents (5.6% vs 2.7%). Overall, females reported a higher rate of reaction to insect stings (27% vs 22%), although there was no difference between sexes for systemic reactions. No statistically significant differences were identified between age or country of birth for reactions to insect stings.
Conclusion: 3.5% of surveyed individuals reported a history consistent with a systemic reaction to an insect sting, with a higher frequency in nonmetropolitan residents but no statistically significant difference according to age or sex. The aim was to provide accessible, consistent, accurate and easy to follow information in an anaphylaxis emergency, and therefore reduce fatal anaphylaxis. These plans are used throughout Australia and New Zealand, the only countries in the world that have only one action plan for anaphylaxis that is completed by medical and nurse practitioners. ASCIA Action Plans for Anaphylaxis are regularly reviewed and updated, and most changes have been based on published data and coronial inquiry recommendations. In 2018 a major update of ASCIA Action Plans for Anaphylaxis included the development of a generic version, which can be used with any brand of adrenaline (epinephrine) autoinjector.
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Method: In 2018 several updates were made to the EpiPen ® versions of the ASCIA Action Plan for Anaphylaxis after an extensive consultation period with the ASCIA membership. A generic version was developed in parallel, which does not include any brand specific adrenaline autoinjector instructions. To ensure accuracy and consistency of information, ASCIA anaphylaxis e-training courses and other ASCIA resources were also updated.
Changes to ASCIA Action Plans: The main changes are:
• New generic versions can be used with any brand of adrenaline autoinjector, with no mention of brand names or brand specific instructions.
• To reduce the risk of prescribing or dispensing the incorrect dose of adrenaline autoinjector, ASCIA prescribing guidelines are now included on version of the plans: Adrenaline autoinjectors (300mcg) are prescribed for children over 20kg and adults; Adrenaline autoinjectors (150mcg) are prescribed for children 10-20kg.
• To minimise the risk of inappropriate treatment and prevent allergic reactions to ticks, the following updated information is included on each plan "For tick allergy seek medical help or freeze tick and let it drop off".
• As a result of new research data, the following wording has been added to each plan;If adrenaline is accidentally injected (e.g. into a thumb) phone your local poisons information centre. Continue to follow this action plan for the person with the allergic reaction.
Conclusion:
In an anaphylaxis emergency, ASCIA Action Plans for Anaphylaxis provide easy to follow information which is consistent and accurate. The generic or EpiPen versions of the ASCIA Action Plan for Anaphylaxis should be completed by a medical or nurse practitioner, for each patient with prescribed adrenaline autoinjectors. The generic versions can be used with any brand of adrenaline autoinjectors. 
